A report from Bloomberg News today said that the biopharma heavyweight Bristol Myers Squibb (NYSE: BMY) might be interested in buying Aurinia Pharmaceuticals for an undisclosed sum. The report also noted that Bristol could still walk away from the negotiations. Rumors of a buyout of Aurinia are nothing new.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting